TY - JOUR
T1 - Semiquantitative Imaging Biomarkers of Knee Osteoarthritis Progression
T2 - Data From the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium
AU - Collins, Jamie E.
AU - Losina, Elena
AU - Nevitt, Michael C.
AU - Roemer, Frank W.
AU - Guermazi, Ali
AU - Lynch, John A.
AU - Katz, Jeffrey N.
AU - Kent Kwoh, C.
AU - Kraus, Virginia B.
AU - Hunter, David J.
N1 - Publisher Copyright:
© 2016, American College of Rheumatology
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Objective: To determine the association between changes in semiquantitative magnetic resonance imaging (MRI) biomarkers over 24 months and radiographic and pain progression over 48 months in knees with mild-to-moderate osteoarthritis (OA). Methods: We undertook a nested case–control study as part of the Foundation for the National Institutes of Health Biomarkers Consortium Project. We used multivariable logistic regression models to examine the association between change over 24 months in semiquantitative MRI markers and radiographic and pain progression in knee OA. MRIs were read according to the MRI OA Knee Score system. We focused on changes in cartilage, osteophytes, meniscus, bone marrow lesions, Hoffa-synovitis, and effusion-synovitis. Results: The most parsimonious model included changes in cartilage thickness and surface area, effusion-synovitis, Hoffa-synovitis, and meniscal morphology (C statistic 0.740). Compared with no worsening, worsening in cartilage thickness in ≥3 subregions was associated with 2.8-fold (95% confidence interval [95% CI] 1.3–5.9) greater odds of being a case, and worsening in cartilage surface area in ≥3 subregions was associated with 2.4-fold (95% CI 1.3–4.4) greater odds of being a case. Worsening of meniscal morphology in any region was associated with 2.2-fold (95% CI 1.3–3.8) greater odds of being a case. Worsening effusion-synovitis and Hoffa-synovitis were also associated with a greater odds of being a case (odds ratios 2.7 and 2.0, respectively). Conclusion: Twenty-four–month changes in cartilage thickness, cartilage surface area, effusion-synovitis, Hoffa-synovitis, and meniscal morphology were independently associated with OA progression, suggesting that these factors may serve as efficacy biomarkers in clinical trials of disease-modifying interventions for knee OA.
AB - Objective: To determine the association between changes in semiquantitative magnetic resonance imaging (MRI) biomarkers over 24 months and radiographic and pain progression over 48 months in knees with mild-to-moderate osteoarthritis (OA). Methods: We undertook a nested case–control study as part of the Foundation for the National Institutes of Health Biomarkers Consortium Project. We used multivariable logistic regression models to examine the association between change over 24 months in semiquantitative MRI markers and radiographic and pain progression in knee OA. MRIs were read according to the MRI OA Knee Score system. We focused on changes in cartilage, osteophytes, meniscus, bone marrow lesions, Hoffa-synovitis, and effusion-synovitis. Results: The most parsimonious model included changes in cartilage thickness and surface area, effusion-synovitis, Hoffa-synovitis, and meniscal morphology (C statistic 0.740). Compared with no worsening, worsening in cartilage thickness in ≥3 subregions was associated with 2.8-fold (95% confidence interval [95% CI] 1.3–5.9) greater odds of being a case, and worsening in cartilage surface area in ≥3 subregions was associated with 2.4-fold (95% CI 1.3–4.4) greater odds of being a case. Worsening of meniscal morphology in any region was associated with 2.2-fold (95% CI 1.3–3.8) greater odds of being a case. Worsening effusion-synovitis and Hoffa-synovitis were also associated with a greater odds of being a case (odds ratios 2.7 and 2.0, respectively). Conclusion: Twenty-four–month changes in cartilage thickness, cartilage surface area, effusion-synovitis, Hoffa-synovitis, and meniscal morphology were independently associated with OA progression, suggesting that these factors may serve as efficacy biomarkers in clinical trials of disease-modifying interventions for knee OA.
UR - http://www.scopus.com/inward/record.url?scp=84988807243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988807243&partnerID=8YFLogxK
U2 - 10.1002/art.39731
DO - 10.1002/art.39731
M3 - Article
C2 - 27111771
AN - SCOPUS:84988807243
SN - 2326-5191
VL - 68
SP - 2422
EP - 2431
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 10
ER -